Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-26 4:15 pm Purchase |
2024-02-16 | 13G | enGene Holdings Inc. Common Stock ENGN |
Venrock Healthcare Capital Partners III L.P. | 2,565,841 5.900% |
2,565,841 (New Position) |
Filing History |
| 2024-02-14 9:20 pm Purchase |
2023-12-31 | 13G | Applied Therapeutics, Inc. APLT |
Venrock Healthcare Capital Partners III L.P. | 7,877,817 9.990% |
2,080,232 (+35.88%) |
Filing History |
| 2024-02-14 9:13 pm Unchanged |
2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Venrock Healthcare Capital Partners III L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 8:56 pm Purchase |
2023-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
Venrock Healthcare Capital Partners III L.P. | 11,328,000 9.400% |
1,650,000 (+17.05%) |
Filing History |
| 2024-02-14 8:56 pm Sale |
2023-12-31 | 13G | Milestone Pharmaceuticals Inc. MIST |
Venrock Healthcare Capital Partners III L.P. | 925,048 2.800% |
-1,283,764 (-58.12%) |
Filing History |
| 2024-02-14 8:53 pm Purchase |
2023-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Venrock Healthcare Capital Partners III L.P. | 2,563,952 6.400% |
668,667 (+35.28%) |
Filing History |
| 2024-02-14 8:53 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.200% |
740,760 (+33.46%) |
Filing History |
| 2024-02-14 8:52 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III L.P. | 4,824,731 14.000% |
1,251,017 (+35.01%) |
Filing History |
| 2024-02-14 8:51 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Venrock Healthcare Capital Partners III L.P. | 4,400,000 8.900% |
1,512,483 (+52.38%) |
Filing History |
| 2024-02-14 8:47 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III L.P. | 3,734,514 9.990% |
3,734,514 (New Position) |
Filing History |
| 2024-02-14 8:45 pm Purchase |
2023-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX |
Venrock Healthcare Capital Partners III L.P. | 823,626 8.900% |
823,626 (New Position) |
Filing History |
| 2024-02-14 8:44 pm Purchase |
2023-12-31 | 13G | RayzeBio, Inc. Common Stock RYZB |
Venrock Healthcare Capital Partners III L.P. | 4,030,471 6.700% |
13,624 (+0.34%) |
Filing History |
| 2024-02-14 8:44 pm Sale |
2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
Venrock Healthcare Capital Partners III L.P. | 10,412,872 5.600% |
-4,031,572 (-27.91%) |
Filing History |
| 2024-02-14 8:42 pm Purchase |
2023-12-31 | 13G | Pharvaris N.V. PHVS |
Venrock Healthcare Capital Partners III L.P. | 3,395,606 6.500% |
912,000 (+36.72%) |
Filing History |
| 2024-02-14 8:38 pm Purchase |
2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 4,497,117 7.300% |
789,226 (+21.29%) |
Filing History |
| 2024-02-14 8:28 pm Purchase |
2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Venrock Healthcare Capital Partners III L.P. | 5,555,568 9.990% |
1,324,947 (+31.32%) |
Filing History |
| 2024-02-14 8:28 pm Purchase |
2023-12-31 | 13G | Celcuity Inc. CELC |
Venrock Healthcare Capital Partners III L.P. | 2,476,980 9.990% |
2,476,980 (New Position) |
Filing History |
| 2024-02-14 8:26 pm Purchase |
2023-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
Venrock Healthcare Capital Partners III L.P. | 1,556,421 7.500% |
966,472 (+163.82%) |
Filing History |
| 2024-02-14 8:26 pm Purchase |
2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Venrock Healthcare Capital Partners III L.P. | 2,070,000 3.300% |
2,070,000 (New Position) |
Filing History |
| 2024-02-14 8:25 pm Purchase |
2023-12-31 | 13G | ABIVAX SA ABVX |
Venrock Healthcare Capital Partners III L.P. | 3,611,570 5.700% |
298,570 (+9.01%) |
Filing History |